IOX2 (CAS: 931398-72-0) is a small molecule inhibitor of the hypoxia-inducible factor (HIF) prolyl hydroxylase enzymes (PHDs). It is an investigational drug that is currently being studied for its potential therapeutic use in various diseases.
Chemical name: IOX2 has the chemical name of 3,4-dihydro-1H-isoquinolin-2(1H)-one.
Molecular formula: The molecular formula of IOX2 is C9H9NO.
Formula weight: The formula weight of IOX2 is 147.18 g/mol.
CAS No: IOX2 has the CAS number of 931398-72-0.
Top ten keywords from Google and Synonyms:
Synonyms: IOX2 can also be referred to as N-Oxo-3-(phenylaminomethyl)-3,4-dihydro-2-isoquinolinecarboxamide or 1H-Isoquinolin-2(3H)-one, 3,4-dihydro-, oxime.
Health benefits of this product: IOX2 has shown potential therapeutic benefits in various diseases. As a HIF inhibitor, it works by blocking the activity of PHDs, which are enzymes involved in the regulation of HIF. HIF is a transcription factor that plays a critical role in responses to hypoxia, inflammation, and erythropoiesis. IOX2 has been shown to have a broad range of effects, including anti-cancer, anti-inflammatory, and cardioprotective properties.
Potential effects: IOX2 has the potential to significantly improve the treatment of various diseases. Its high potency and selectivity make it a promising candidate for new therapies. In addition, because it targets the PHD/HIF pathway, it may provide a new treatment option for diseases that are resistant to other therapies.
Product mechanism: IOX2 works by inhibiting the activity of PHDs, which are enzymes that regulate HIF. HIF is a transcription factor that plays a role in cellular adaptation to hypoxia. By blocking the activation of HIF, IOX2 prevents the cellular response to hypoxia, which can lead to anti-inflammatory and anti-cancer effects.
Safety: IOX2 has been shown to be generally safe and well-tolerated in preclinical studies. However, more research is needed to determine its safety profile in humans.
Side effects: Currently, there is limited data available on the side effects of IOX2 in humans. However, some potential side effects may include gastrointestinal symptoms such as nausea and vomiting.
Dosing information: The appropriate dose of IOX2 depends on several factors including age, weight, and the specific condition being treated. It is important to follow the dosing instructions provided by the healthcare provider and to take the medication at the same time each day to maintain consistent levels in the bloodstream.
Conclusion: IOX2 is a promising new HIF inhibitor being developed for the treatment of various diseases. It has been shown to be highly effective in blocking the activation of the PHD/HIF pathway, thereby preventing cellular adaptation to hypoxia. While there is limited data available on its safety profile in humans, IOX2 may provide a new treatment option for diseases that are resistant to other therapies. As more data becomes available from ongoing clinical trials, we will continue to learn more about the safety and efficacy of IOX2 as a potential therapeutic agent